ArticleInternational journal of general medicine2025
Glycosylation-Related Genes and Prognostic Signatures in Diabetic Nephropathy.
Article in International journal of general medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Diabetic nephropathy (DN) is the leading cause of end-stage renal disease worldwide, whose pathogenesis involves immune dysregulation and inflammatory response. Glycosylation plays key roles in numerous biological processes. This study aims to interrogate the role of glycosylation-related genes in tubulointerstitial immunoinflammatory injury in DN. Methods: We utilized two tubulointerstitial transcriptome datasets from DN patients and normal individuals. Glycosylation-related hub genes were identified by integrating differential expression analysis, glycosylation-related gene sets, and machine learning. Immune cell infiltration was assessed using single-sample GSEA (ssGSEA), and functional enrichment analysis was performed via GO and KEGG. The expression levels of hub genes were validated in STZ-induced diabetic mouse model (n=5/group) followed by the evaluation of diagnostic efficiency and clinical significance. Results: Six glycosylation-related hub genes (HEXB, B4GALT5, GALNT7, GCNT3, CGA, and VCAN) were identified, all closely associated with immune cell infiltration in DN. Enrichment analysis indicated their involvement in immune and inflammatory processes. CGA was significantly downregulated, while the other genes were upregulated in DN, which was experimentally validated in diabetic mice. ROC curve analysis revealed high diagnostic accuracy for all genes: HEXB (AUC = 0.892), B4GALT5 (AUC = 0.909), GALNT7 (AUC = 0.931), GCNT3 (AUC = 0.929), CGA (AUC = 0.898), and VCAN (AUC = 0.967). Elevated VCAN, GCNT3, and GALNT7 exhibited a positive association with renal function decline or proteinuria, providing valuable prognostic insights. Conclusion: This study highlights the significant role of glycosylation-related genes in DN pathogenesis, likely mediated through immune and inflammatory mechanisms. VCAN, GCNT3, and GALNT7 show particular promise as novel biomarkers for clinical diagnosis and immunotherapeutic targets, supporting their future clinical translation for DN management.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.